Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Glepaglutide.

Research draft

Glepaglutide is a long-acting GLP-2 analogue investigated for short bowel syndrome.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Glepaglutide is a long-acting GLP-2 analogue investigated for short bowel syndrome.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It promotes intestinal adaptation and absorption-related responses.

Human research

Randomised phase 2 and phase 3 research measured reductions in parenteral support; findings are specific to short bowel syndrome.

Preclinical & other research

Intestinal models support the adaptation rationale.

Safety & unknowns

Fluid balance, gastrointestinal effects and relevant disease monitoring matter.

Regulatory status

Trial evidence and any local authorisation must be assessed separately.

Reported use & evidence

Research profile draft

The supplied Glepaglutide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds